wait risk continu
ew share open weaker friday follow releas result
versu flat sale bit better expect due critic
surgic structur heart sale well lower fx headwind transcathet
heart valv therapi sale in-lin dollar basi littl weaker
underli growth perspect ew guid street expect though
werent surpris given management comment slower growth dec
analyst day full year guidanc metric re-affirmed net/net noth realli
chang view stock believ expect upcom
risk trial releas march confer high market
share eros like ahead addit valv come market also think
transcathet mitral triscupid opportun may take longer materi
key takeaway result call follow-up convers
ew lost tavr share y/i basi compani comment due
decis exercis price disciplin
comment risk studi management want engag
convers trial come soon comment
outlook incorpor view posit outcom think studi
favor worri market expect may high
adjust ep estim better reflect cadenc expens weve
modestli rais ep estim maintain price target
what next crt confer intervent cardiolog meet held
march meet like commentari transcathet valv
market ew program big date march low risk data
present confer
ew quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
underweight believ sale growth like
slow edward face competit transcathet
aortic valv tavr expect limit leverag
edward invest transcathet mitral valv
tmvr/r opportun sale ep estim
street tmvr/r repres potenti
second act still risk like
upsid case may driven better-than-
expect tavr sale greater leverag
stronger uptak tmvr europ faster-
than-expect time tmvr/r product
downsid case may driven delay
inabl commerci tmvr/r technolog
slowdown tavr sale due market slowdown
and/or competit pressur fx rate
greater expens support tmvr/r
sale street mainli driven higher critic structur
heart valv sale thvt sale in-lin underli sale ep
line street estim toward upper end
guidanc rang edward re-affirmed full year guidanc
rang provid analyst day decemb guidanc
street expect net/net noth chang view outlook
million except per share data chang sale constant currenc organ basi unless otherwis note
addit detail quarter
previou guidanc rang re-affirmed
gross margin improv y/i benefit foreign exchang
hedg product mix absenc expens closur swiss
manufactur plant off-set invest capac
critic sale better-than-expect underli sale growth
led hemospher growth enhanc recoveri product
transcathet heart valv therapi thvt sale in-lin street
dollar basi constant currenc basi growth littl lighter
manag target thought growth would line
trend think market hope mayb given
continu roll-out albeit control centera sapien ultra
manag guid metric street see detail
ew note lost share europ y/i basi maintain price
disciplin note share sequenti stabl
sale underli basi underli growth divis
transcathet heart valv therapi structur heart critic
gross margin y/i benefit fx rate
sg sale y/i
 sale y/i edward continu invest clinic trial
transcathet structur heart program
oper margin y/i larg driven oper expans
effect busi manag
adjust tax rate y/i includ benefit
stock-bas compens
adjust ep in- line street estim
edward expect sale versu street pre-releas ep versu street pre-
edward reiter full year guidanc rang continu expect sale rang
underli though currenc expect slightli less headwind versu underli basi ew expect
transcathet aortic valv replac tavr growth surgic structur heart growth critic growth
transcathet mitral tricuspid therapi tmtt sale expect gross profit margin anticip
oper margin adjust tax rate expect net/net ew maintain adjust ep
target
actual million salesrptdex fx/org transcathet heart heart street divis estim streetaccount els refinitivyoy barclay edward lifesci corp
abbrevi incom statement million except per share data
incom statementnet oper inc inc barclay edward lifesci corp
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
